This has led to the preclinical and clinical development of various IL-6/STAT3 inhibitors targeting the IL-6/JAK/STAT3 components in order to inhibit tumor growth and reduce immunosuppression in the tumor microenvironment [34]. The gene discussed is STAT3; the disease is neoplasm.